title: Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study.
abstract: Anti-cholinergic agents are considered the bronchodilator therapy of first-choice in the treatment of patients with stable chronic obstructive pulmonary disease (COPD) associated with heart disease since they may be as effective or more effective than inhaled beta2-agonists and, moreover, they do not interact with cardiac beta-adrenoceptors. The aim of our study was to evaluate the bronchodilator activity of oxitropium bromide in outpatients suffering from exacerbations of COPD associated with heart diseases (ischaemic heart disease and/or arrhythmias). We recruited 50 consecutive outpatients (33 males and 17 females, mean age 68.6 years, 15 current smokers and 35 ex-smokers). Each patient performed body plethismography in basal condition and 30 min after inhalation of 200 microg metered dose inhaler (MDI) oxitropium bromide administered by a device (Fluspacer). FEV1, FVC, MMEF25-75, sRaw and tRaw were evaluated. Thirty minutes after 200 microg oxitropium bromide administration, we observed a significant improvement in FEV1 11.6% +/- 1 (mean +/- SEM) (P<0.01); FVC, MMEF25-75 sRaw variation was respectively: 9.2% +/- 0.6, 31.4 +/- 2.9, -19.9 +/- 1.1. Placebo did not significantly change pulmonary function. Our data suggest that oxitropium bromide bronchodilator activity is effective in exacerbations of COPD.
authors.affiliation: Institute of Lung Disease, Respiratory Unit, San Paolo Hospital, University of Milan, Itlay.
authors.forename: S
authors.initials: S
authors.lastname: Centanni
authors.forename: P
authors.initials: P
authors.lastname: Santus
authors.forename: F
authors.initials: F
authors.lastname: Casanova
authors.forename: P
authors.initials: P
authors.lastname: Carlucci
authors.forename: B
authors.initials: B
authors.lastname: Boveri
authors.forename: F
authors.initials: F
authors.lastname: Castagna
authors.forename: F
authors.initials: F
authors.lastname: Di Marco
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
mesh_terms: D000208:Acute Disease; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D012907:Smoking; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; C017590:oxitropium